logo-loader
viewFrontier IP Group PLC

Coronavirus vaccine news "false dawn" for markets, analyst says

The first human trials have started in the US while Russia and China are ramping up developments too

Frontier IP Group PLC -

The pharma industry has been ramping up studies for coronavirus vaccines, with biotech company Moderna Inc (NASDAQ:MRNA) testing on humans for the first time this week and Chinese, Russian and Australian companies also reporting new vaccine developments since Monday.

However, some experts say stock markets are not likely to stage a proper recovery yet and such news from the biotech sector should be false dawns for investors.

READ: Small biotechs buck market trend as search for lung infection relief intensifies

Share prices will be determined by the extent of the spread of the disease and measures governments put in place to halt the damage to the economy, said Helal Miah, analyst at the Share Centre.

“Markets will react to false dawns too amid data releases suggesting a slowing of the spread or even rumours or fake news of a vaccine,” Miah said.

For instance, Chinese media reported on Tuesday that the country's Academy of Military Medical Sciences was given the green light to kick off clinical trials.

Similarly, the Vector Institute in Siberia was said to have started testing some prototypes and will present the most effective one in three months’ time.

Many scientists around the globe are certain to benefit from a discovery made by the Doherty Institute in Australia, mapping how patients’ immune system responds to the virus.

According to the study, it can help in the development of vaccines and treatment, but the timescale of drug developments, including important regulatory hurdles, means the effects will not be imminent. 

Looking ahead, Frontier IP Group PLC (LON:FIPP) is, for example, looking to “imminently” start trials on animals, as told to Proactive on Monday.

"While some investors may begin to ask whether we are close to the bottom, others will see further downside potential and I sit in this camp," Miah said.

"We are only just at the start of the crisis in the UK and judging by what’s going on in Europe we have the disastrous economic consequences to deal with in the coming months."

As for the short-term effect on economies and markets, Miah added: "A V-shaped recovery is not on the cards.”

Quick facts: Frontier IP Group PLC

Price: 64.9 GBX

AIM:FIPP
Market: AIM
Market Cap: £32.89 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP 'in strong position' and working closely with portfolio...

Frontier IP Group PLC's (LON:FIPP) Neil Crabb speaks to Proactive London's Andrew Scott to discuss how the Intellectual property specialist's portfolio companies are adapting to the new virus threat. Crabb also touches on new investee company Elute Intelligence, in which it holds a 43% stake,...

2 hours, 1 minute ago

2 min read